Maged G Ramsy, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2720 Bristol St, Santa Ana, CA 92704 Phone: 888-499-9303 Fax: 714-557-2251 |
Ashley Reiko Bone, CPNP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2650 S Bristol St # 101-103, Santa Ana, CA 92704 Phone: 714-754-1444 |
Dr. Teri Klein Christy, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 3401 S Harbor Blvd, Santa Ana, CA 92704 Phone: 714-830-6590 |
Jesil Joy Pazhayampallil, Pediatrics Medicare: Medicare Enrolled Practice Location: 2212 E 4th St, Santa Ana, CA 92705 Phone: 714-571-7700 |
Dr. Joanne Liang, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 800 N Main St, Santa Ana, CA 92701 Phone: 657-282-6355 |
Dr. Hung I Chen, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1125 E 17th St, N354, Santa Ana, CA 92701 Phone: 714-569-0388 Fax: 714-569-1018 |
Sneh Khurana, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1400 N Main Street, Santa Ana, CA 92701 Phone: 714-541-6815 Fax: 714-541-8032 |
Dr. Faraz Valaie, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 15 Macarthur Place, #601, Santa Ana, CA 92707 Phone: 818-917-5407 |
News Archive
Sanofi announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc., for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.
Chronic conditions including obesity, cardiovascular disease, and cancer often begin with early, subtle changes in cellular metabolism.
Smaller lymph nodes commonly seen on abdominal CT scans in "healthy" people are not clinically significant and require no further imaging, a new study confirms. The study was performed because there is no standard as to what should be done about these patients so they often undergo additional testing to rule out inflammation, cancer or other diseases.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088.
› Verified 6 days ago